BioPharmSignal logoBioPharmSignal

Biotech News

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

Immix Biopharma (IMMX)Immix BiopharmaFinancing

- Financing includes leading U.S. biotechnology institutional investors and mutual funds -

LOS ANGELES, CA, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "we" or "us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the closing of its...

Related news

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

IMTXImmatics2026-08-25 11:00 EST

Immatics Announces $150 Million Underwritten Offering

ZNTLZentalis2026-08-17 20:01 EST

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

REPLReplimune Group2026-08-10 12:00 EST

Replimune Announces Pricing of $150 Million Underwritten Offering

ZNTLZentalis2026-08-14 02:23 EST

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-22 20:05 EST

Biomea Fusion Announces Proposed Public Offering of Securities

IMMXImmix Biopharma2026-10-05 13:45 EST

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

KURAKura Oncology2026-09-09 11:00 EST

Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes

TEVATeva Pharmaceutical Industries2026-09-07 07:53 EST

Teva Announces Launch of Offering of Senior Notes

View all latest news

Immix Biopharma

Immix Biopharma is a biotechnology company focused on immune-driven therapies and oncology programs. Its strategy centers on translating immune biology into targeted treatment options.

Recent company news

IMMXImmix Biopharma2026-10-05 13:45 EST

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-30 22:15 EST

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

IMMXImmix Biopharma2026-09-29 12:05 EST

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Stock data

Close
10.23 USD
Market cap
595.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States